WO1991004273A3 - Novel peptides associated with the cd4 binding region of gp120 and their methods of use - Google Patents

Novel peptides associated with the cd4 binding region of gp120 and their methods of use

Info

Publication number
WO1991004273A3
WO1991004273A3 PCT/US1990/005393 US9005393W WO9104273A3 WO 1991004273 A3 WO1991004273 A3 WO 1991004273A3 US 9005393 W US9005393 W US 9005393W WO 9104273 A3 WO9104273 A3 WO 9104273A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
binding region
novel peptides
peptides associated
neutralizing epitope
Prior art date
Application number
PCT/US1990/005393
Other languages
French (fr)
Other versions
WO1991004273A2 (en
Inventor
Thomas Kieber-Emmons
William John Woodrow Morrow
William H Rastetter
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of WO1991004273A2 publication Critical patent/WO1991004273A2/en
Publication of WO1991004273A3 publication Critical patent/WO1991004273A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Novel synthetic peptides and analogs thereof are provided that represent a neutralizing epitope in the external envelope glycoprotein (gp120) of the human immunodeficiency virus (HIV) that is purportedly involved in the binding of this molecule to its cellular receptor, CD4. Also provided are methods of generating antibodies reactive with or containing the internal image of the neutralizing epitope. The peptides or antibodies may be used in diagnostic immunoassays, as vaccines or in immunotherapy.
PCT/US1990/005393 1989-09-22 1990-09-21 Novel peptides associated with the cd4 binding region of gp120 and their methods of use WO1991004273A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41106389A 1989-09-22 1989-09-22
US411,063 1989-09-22
US58494890A 1990-09-18 1990-09-18
US584,948 1990-09-18

Publications (2)

Publication Number Publication Date
WO1991004273A2 WO1991004273A2 (en) 1991-04-04
WO1991004273A3 true WO1991004273A3 (en) 1991-05-02

Family

ID=27021259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/005393 WO1991004273A2 (en) 1989-09-22 1990-09-21 Novel peptides associated with the cd4 binding region of gp120 and their methods of use

Country Status (6)

Country Link
EP (1) EP0493508A1 (en)
AU (1) AU6523590A (en)
CA (1) CA2066607A1 (en)
IE (1) IE903433A1 (en)
IL (1) IL95824A0 (en)
WO (1) WO1991004273A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637677A (en) 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
WO1990012868A1 (en) * 1989-04-25 1990-11-01 Tanox Biosystems, Inc. Antibodies specific for cd4-binding domain of hiv
AU647108B2 (en) * 1990-04-03 1994-03-17 Genentech Inc. Methods and compositions for vaccination against HIV
US7041293B1 (en) 1990-04-03 2006-05-09 Genentech, Inc. HIV env antibodies
AP237A (en) * 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
CA2047042A1 (en) * 1990-07-19 1992-01-20 John Hannah Cyclic hiv principal neutralizing determinant peptides
CA2047033A1 (en) * 1990-07-19 1992-01-20 Elizabeth E. Sugg Cyclic hiv principal neutralizing determinant peptides
CA2047078A1 (en) * 1990-07-19 1992-01-20 Steven S. Bondy Cyclic hiv principal neutralizing determinant peptides
EP0551440B1 (en) * 1990-09-14 2002-12-18 The Trustees Of The University Of Pennsylvania Design of bioactive peptides based on immunoglobulin structure
JPH05262662A (en) * 1991-07-15 1993-10-12 Calpis Food Ind Co Ltd:The Hiv superinfection preventive, antigen for preparing anti-idiotype antibody and production of anti-idiotype antibody
EP0652764B1 (en) * 1992-02-10 2000-05-24 Duke University Use of synthetic peptides to induce tolerance to pathogenic t and b cell epitopes of autoantigens
US5556744A (en) * 1992-05-29 1996-09-17 The Trustees Of The University Of Pennsylvania Methods and compositions for diagnosing and treating certain HIV infected patients
EP0708659A4 (en) * 1993-06-07 2000-08-23 Genentech Inc Hiv envelope polypeptides
CA2181590C (en) * 1994-01-19 2009-01-06 Frank A. Robey Peptomers with enhanced immunogenicity
DE4405810A1 (en) 1994-02-23 1995-08-24 Behringwerke Ag Peptides derived from a retrovirus from the HIV group and their use
US5691447A (en) * 1995-03-24 1997-11-25 Tanox Biosystems, Inc. GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
ZA975889B (en) * 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
US6585979B1 (en) 1996-07-08 2003-07-01 Genentech, Inc. HIV envelope polypeptides and immunogenic composition
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
ATE384795T1 (en) 1998-12-31 2008-02-15 Novartis Vaccines & Diagnostic MODIFIED HIV ENV POLYPEPTIDES
EP1141314A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2001254567A1 (en) * 2000-05-02 2001-11-12 Simon Fraser University Polypeptides for use as a vaccine and/or treatment for hiv infection
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US20100009340A1 (en) * 2006-04-05 2010-01-14 The Regents Of The University Of California Compositions and methods for the analysis and treatment of aids wasting syndrome and immune cell dysfunction
ES2593789T3 (en) * 2007-02-01 2016-12-13 Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Specific activation of a regulatory T cell and its use for the treatment of asthma, allergic diseases, autoimmune diseases, graft rejection and tolerance induction
EP2452947A1 (en) * 2010-11-16 2012-05-16 Münch, Jan Viral infection enhancing peptide
EP2492279A1 (en) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
EP2698377A1 (en) 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Enhanced rapid immunogen selection method for HIV gp120 variants

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273716A2 (en) * 1986-12-30 1988-07-06 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins
EP0279688A2 (en) * 1987-02-20 1988-08-24 Genentech, Inc. Methods and compositions for the use of HIV env polypeptides and antibodies thereto
EP0306219A2 (en) * 1987-08-27 1989-03-08 Repligen Corporation Novel HIV proteins and peptides useful in the diagnosis, prophylaxis or therapy of AIDS
EP0328403A2 (en) * 1988-02-12 1989-08-16 United Biomedical Inc. Synthetic peptides related to the HIV-GP120-env-protein, and their use
EP0330359A2 (en) * 1988-02-25 1989-08-30 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of HIV-1 infection

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273716A2 (en) * 1986-12-30 1988-07-06 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins
EP0279688A2 (en) * 1987-02-20 1988-08-24 Genentech, Inc. Methods and compositions for the use of HIV env polypeptides and antibodies thereto
EP0306219A2 (en) * 1987-08-27 1989-03-08 Repligen Corporation Novel HIV proteins and peptides useful in the diagnosis, prophylaxis or therapy of AIDS
EP0328403A2 (en) * 1988-02-12 1989-08-16 United Biomedical Inc. Synthetic peptides related to the HIV-GP120-env-protein, and their use
EP0330359A2 (en) * 1988-02-25 1989-08-30 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of HIV-1 infection

Also Published As

Publication number Publication date
IL95824A0 (en) 1991-06-30
WO1991004273A2 (en) 1991-04-04
AU6523590A (en) 1991-04-18
CA2066607A1 (en) 1991-03-23
IE903433A1 (en) 1991-04-10
EP0493508A1 (en) 1992-07-08

Similar Documents

Publication Publication Date Title
WO1991004273A3 (en) Novel peptides associated with the cd4 binding region of gp120 and their methods of use
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
CA2082948A1 (en) Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding
NZ219113A (en) Hiv peptide containing epitope of the env protein
RU96102594A (en) TANDEM SYNTHETIC HIV-1 PEPTIDES
EP0339504A3 (en) Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
CA2164818A1 (en) Tandem synthetic hiv-1 peptides
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
CA2143163A1 (en) Peptides derived from a retrovirus of the hiv group, and their use
WO1989006276A3 (en) Hiv-2-type retroviruses of primates, vaccines, diagnostic and pharmaceutical compositions
CA2091263A1 (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
EP0284587A3 (en) Synthetic peptide antigens for the detection of hiv-1 infection
EP0225066A3 (en) Antigen determinant peptides and a process for the preparation thereof
ATE135743T1 (en) MONOCLONAL HUMAN ANTIBODIES AGAINST HIV-I
IL127595A0 (en) Polypeptides capable of forming antigen binding structures with specificity for the rhesus D antigens the DNA encoding them and the process for their preparation and use
CA2135630A1 (en) Hiv protein epitopes immunologically homologous to hla
WO1991015512A3 (en) Hiv envelope polypeptides
AU608413B2 (en) Mouse monoclonal antibody (5-21-3) to human immunodeficiency virus gp41 protein
SG44828A1 (en) New soluble non-cleavable gp160 variant of hybrid form
EP0320866A3 (en) A protective immunodominant epitope included in the s1 subunit of pertussis toxin
CA2160696A1 (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
WO1989009227A3 (en) Pf10 to pf19 peptides of an hiv retrovirus, process for synthetizing said peptides and their use, in particular for diagnosis
WO2002069691A3 (en) Immunogenic hiv peptides for use as reagents and vaccines
Birx et al. HIV vaccine therapy
WO1990013314A3 (en) Antigenes of the envelope transmembrane glycoprotein of a human retrovirus of the hiv-2 type, and antigens presenting with them an immunological relationship

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA FI JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA FI JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2066607

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1990915005

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1990915005

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1990915005

Country of ref document: EP